Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 9 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
The Korea Research Institute of Bioscience and Biotechnology is currently overseeing 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 11 distinct examiners, indicating a broad engagement with the patent office's staff. The portfolio is also spread across 8 distinct art units, which highlights the diverse range of biological and pharmaceutical research being pursued by the institute. This variety in art units suggests that the pending applications cover several different specialized scientific domains.
REYNOLDS, FRED H is the busiest examiner for the portfolio, currently handling 2 pending office actions. Given that there are 12 total pending actions, the workload is relatively evenly spread among the 11 distinct examiners. This distribution minimizes the impact of any single examiner on the overall success of the portfolio. The presence of 8 distinct art units means that the institute must navigate a complex regulatory environment with varying examination standards. Practitioners will need to tailor their strategies to the specific requirements of each of the 11 examiners.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §101 + other | 1 (8%) |
| §103 only | 2 (15%) |
| §102 only | 1 (8%) |
| §112 only | 2 (15%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 2 | 33.0% | +39.2% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| GAMBLE JR, RANDALL LEE | 1 | 51.4% | +27.6% |
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.5% | +57.4% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
| THUESON, HANNA MARIE | 1 | 76.7% | +28.2% |
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | THUESON, HANNA MARIE | 46d overdue |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 7d |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 61d |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | — |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | REYNOLDS, FRED H | — |
| 18037222 | COMPOSITION FOR DETECTING TARGET NUCLEIC ACID AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | GIAMMONA, FRANCESCA FILIPPA | — |
| 17609871 | METHOD AND COMPOSITION FOR DETECTING THYROID CANCER-SPECIFIC DNA METHYLATION BIOMARKER FOR DIAGNOSIS OF THYROID CANCER | TURPIN, ZACHARY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | THUESON, HANNA MARIE | 46d overdue |
| 17767425 | MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 45d overdue |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 7d |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 61d |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | — |
| 18290668 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME | NATARAJAN, MEERA | — |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | REYNOLDS, FRED H | — |
| 18003757 | IMPEDANCE-BASED INTESTINAL ORGANOID EVALUATION SYSTEM | GAMBLE JR, RANDALL LEE | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1631 | 2 |
| 1618 | 1 |
| 1635 | 1 |
| 1795 | 1 |
| 1681 | 1 |
| 1652 | 1 |
| 1638 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | — | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18290668 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME | NATARAJAN, MEERA | — | §102 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18289333 | COMPLEX FOR BIOIMAGING, AND DIAGNOSIS OR TREATMENT OF CANCER | BAEK, JONGHWAN NMN | 1618 | §103 | Final Rejection | — | Pending | Nov 02, 2023 |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 1635 | §103§112Other | Non-Final OA | 7d | Pending | Sep 22, 2023 |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | REYNOLDS, FRED H | 1658 | §101 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18003757 | IMPEDANCE-BASED INTESTINAL ORGANOID EVALUATION SYSTEM | GAMBLE JR, RANDALL LEE | 1795 | §112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18037222 | COMPOSITION FOR DETECTING TARGET NUCLEIC ACID AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112 | Non-Final OA | — | Pending | May 16, 2023 |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 1658 | §101§102§103 | Final Rejection | 61d | Pending | May 04, 2023 |
| 17767425 | MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102DP | Final Rejection | 45d overdue | Pending | Apr 07, 2022 |
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | THUESON, HANNA MARIE | 1638 | §102§103§112 | Final Rejection | 46d overdue | Pending | Mar 04, 2022 |
| 17609871 | METHOD AND COMPOSITION FOR DETECTING THYROID CANCER-SPECIFIC DNA METHYLATION BIOMARKER FOR DIAGNOSIS OF THYROID CANCER | TURPIN, ZACHARY MARK | 1682 | §102§103§112 | Non-Final OA | — | Pending | Nov 09, 2021 |
| 17598916 | METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF | ZHU, JIANJIAN | 1631 | §112Other | Non-Final OA | 9d | Pending | Sep 28, 2021 |
| 17231278 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | MIANO, JOSEPH PAUL | 1631 | §103 | Final Rejection | 16d overdue | Pending | Apr 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial